Tags : ABM-1310

Medicilon Assists ABM Therapeutics to Obtain US FDA Orphan Drug Qualification for ABM-1310 for the T

Medicilon Assists ABM Therapeutics to Obtain US FD..

A Story by Medicilon


Shanghai, China/San Diego,USA - August 2, 2023, ABM Therapeutics announced that its self-developed small molecule BRAF inhibitor ABM-1310 has obtained..